Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 28 June 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Scoring systems for the management of alcoholic hepatitis

The latest issue of the Alimentary Pharmacology & Therapeutics compares scoring systems for the management of alcoholic hepatitis.

News image

The assessment of alcoholic hepatitis remains controversial.

Several scores have been developed or used for this purpose.

Dr Lafferty and colleagues from the United Kingdom used the Glasgow Alcoholic Hepatitis Score, the Discriminant Function, Model for End-Stage Liver Disease and the ABIC scores, as well as scores to assess corticosteroid response in the management of alcoholic hepatitis.

A total of 182 patients were studied prospectively.

The team recorded the Glasgow Alcoholic Hepatitis Score, Model for End-Stage Liver Disease, ABIC and DF scores on admission and serially over the first week of hospital management.

Treatment with corticosteroids or pentoxifylline was considered if the Glasgow Alcoholic Hepatitis Score was 9.

Patients treated with corticosteroids who had a fall in bilirubin of 25%
Alimentary Pharmacology & Therapeutics

There were no differences in outcome between favorable scores as per recommended cut-off points.

The doctors noted that patients with a Glasgow Alcoholic Hepatitis Score less than 9 had similar outcome whether their Model for End-Stage Liver Disease, DF or ABIC scores were favorable or unfavorable.

Treated patients with a Glasgow Alcoholic Hepatitis Score of 9 had a significantly better 90-day outcome than those who did not, at 58% and 30% respectively.

Patients treated with corticosteroids who had a fall in bilirubin of 25% after a week of treatment had an improved survival.

The team found that Lille Score or a 25% fall in bilirubin had greater sensitivities than an early change in bilirubin level to assess treatment response.

Dr LAfferty's team concludes, "In this single-centre study, a Glasgow Alcoholic Hepatitis Score 9 identified patients who may benefit from treatment of alcoholic hepatitis."

"Intention-to-treat randomised-controlled trials using a Glasgow Alcoholic Hepatitis Score =9 as the threshold for treatment are needed to validate these findings."

"Response to corticosteroids can be assessed using the Lille Score or by a 25% fall in bilirubin."

Aliment Pharmacol & Ther 2013: 38(6) 603–610
30 August 2013

Go to top of page Email this page Email this page to a colleague

 28 June 2016 
Cancer recurrence after immune-suppressive therapies
 28 June 2016 
Acute severe ulcerative colitis
 28 June 2016 
Gastric cancer screening in the USA
 27 June 2016 
Epidemiology of NAFLD
 27 June 2016 
Tobacco smoking and ulcerative colitis
 27 June 2016 
The Toronto Consensus for H. pylori treatment
 24 June 2016 
Fibre for chronic idiopathic constipation
 24 June 2016 
Dietary trends in the USA
 24 June 2016 
Statins and colorectal cancer in IBD
 23 June 2016 
Adverse events after colonoscopy bowel preparations
 23 June 2016 
Touch screens in the IBD outpatient clinic
 23 June 2016 
Biomarker for eosinophilic esophagitis diagnosis
 22 June 2016 
IBS symptoms in IBD
 22 June 2016 
Benefits and harms of colorectal cancer screening
 22 June 2016 
Outcomes among US veterans with Hep B
 21 June 2016 
Screening for colorectal cancer
 21 June 2016 
Tenofovir and Hep B transmission in mothers
 21 June 2016 
Access to liver subspecialty care and survival
 20 June 2016 
Genes for colorectal cancer risk
 20 June 2016 
Patients and gastroenterologists’ perceptions on IBD
 20 June 2016 
Hep C treatment in people who inject drugs
 17 June 2016 
Noninvasive markers of liver fibrosis
 17 June 2016 
Predictors of starting with long-term PPIs
 17 June 2016 
Extrahepatic manifestations of Hep C
 16 June 2016 
Endotracheal intubation and endoscopy unit efficiency metrics
 16 June 2016 
Assessing progression of NAFLD
 16 June 2016 
Bile acid diarrhea
 15 June 2016 
Consensus for acute severe ulcerative colitis
 15 June 2016 
Dental erosions in GERD
 15 June 2016 
Pharmacological treatments for obesity with weight loss
 14 June 2016 
Antibiotics and gut inflammation
 14 June 2016 
Liver-related mortality in the developed world
 14 June 2016 
Hep C patient outcomes treated with different anti-viral regimens
 13 June 2016 
Obesity in the USA
 13 June 2016 
Celiac disease drug development
 13 June 2016 
Pneumonia risk in celiac disease
 10 June 2016 

Celiac disease drug development

 10 June 2016 
Rectal cancer surgery checklist
 10 June 2016 
Breath as a marker for IBS
 09 June 2016 
Psychological morbidity in young people with IBD
 09 June 2016 
Predicting hepatic encephalopathy in cirrhosis
 09 June 2016 
Evaluation of endoscopic findings from patients with Crohn's
 08 June 2016 
Adult obesity trends in the USA
 08 June 2016 
Pediatric IBD unclassified vs other IBD
 08 June 2016 
Dark chocolate and NASH oxidation
 07 June 2016 
Flexible endoscopy for Zenker's diverticulum
 07 June 2016 
Predicting risk of hepatic encephalopathy in cirrhosis
 07 June 2016 
Electronic learning system for colon capsule endoscopy
 06 June 2016 
Disturbed sleep and symptoms in IBS
 06 June 2016 
Oral contraceptives and Crohn’s complications
 06 June 2016 
Eosinophilic esophagitis
 03 June 2016 
Antibiotic prophylaxis in cirrhosis
 03 June 2016 
Mortality in hospitalized peptic ulcer patients
 03 June 2016 
Decision aid for surgical patients with ulcerative colitis
 02 June 2016 
Allergy tests for eosinophilic esophagitis
 02 June 2016 
Fatty liver disease and mortality
 02 June 2016 
Ethnic inequalities in rectal cancer care
 01 June 2016 
Predicting NASH resolution
 01 June 2016 
Predicting relapse in IBD
 01 June 2016 
Treatment of Hep C/HIV after liver transplant

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us